A promising new oral β2 adrenergic receptor agonist exhibiting GRK-biased signaling emerges as a potential alternative to injectable GLP-1 receptor agonists in treating type 2 diabetes and obesity. Developed by Atrogi AB and published in Cell, the molecule activates skeletal muscle metabolism to improve glucose regulation and promote fat loss without typical GLP-1 side effects such as appetite loss or gastrointestinal issues. Early phase clinical trials demonstrate tolerability in both healthy volunteers and diabetic patients. The agent may be used alone or in combination with GLP-1 therapies, expanding therapeutic options for metabolic diseases with advantages in administration and muscle mass preservation.